Cynthia A. Challener

Collaboration and single-use technologies aided the rapid scale-up of Ebola vaccine manufacturing

The production of antibody-drug conjugates requires biopharmaceutical and chemical manufacturing, and conjugation capabilities.

Bioprocess operations-from cell line selection to final filtration-can influence the consistency and purity of biologic drug substances.

Determining the appropriate amount and type of screening challenges drug developers when identifying relevant crystalline forms.

Manufacturing highly toxic compounds in a biopharmaceutical environment tests equipment and systems.

Gauging the adequate level and type of screening is the challenge when identifying relevant crystalline forms.

Scale-down modeling accelerates the development of downstream biopharma manufacturing processes.

Hazardous reagents can prove to be faster, simpler, cheaper, and greener.

Nanoscale catalysts and engineered nanoparticles show promise for API synthesis and delivery.

Scale-down modeling is instrumental in supporting the development of downstream biopharma manufacturing processes.

Hazardous reagents can simplify processes and provide higher yields and purities.

Time and sensitivity are essential for analytical technologies in all phases of biopharma development.

Despite fewer FDA approvals in 2015, the prospects for the API market in 2016 are strong.

Nanoscale catalysts and engineered nanoparticles may have a big impact on small-molecule pharmaceuticals.

A strong API market is expected in 2016 despite fewer new drug approvals.

Multi-component coupling reactions for the generation of heterocycles in fewer steps reduced processing times, cost, and waste are attracting interest.

In the ongoing search for better fluorinating reagents, solid reagents and new coupling reactions are showing promise.

Efficient syntheses are possible using multi-component and cross-dehydrogenative, heteroaromatic C–H silylation reactions

Efficient syntheses are possible using multi-component and cross-dehydrogenative, heteroaromatic C-H silylation reactions.

The use of low-temperature chemistry can often lead to more direct, cost-effective routes to sophisticated pharmaceutical compounds.

Safer solid reagents and new coupling chemistry are important developments.

More complex drug candidates require more specialized and selective chemistry.

The complex task of stabilizing proteins is made more challenging due to the limited number of approved excipients.

Early adopters look to speed up the use of continuous API manufacturing, but lack of expertise hinders adoption of continuous API synthesis.

Potential for improved product quality and cost/time savings is reviving interest in perfusion technology.

Potential for improved product quality and cost/time savings is reviving interest in perfusion technology.

FDA, Congress, and early adopters look to speed up the use of continuous API manufacturing.

Safer reagents and reaction conditions are making many hazardous transformations possible.

Safer reagents and reaction conditions are making many hazardous transformations possible.

Research groups supported by industry tackle the challenges of continuous crystallization and process analytical technology.